"the Randomized Placebo-controlled FUTURE 2 Study Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic" by Zailong Wang

Article

the Randomized Placebo-controlled FUTURE 2 Study Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic

(2017)

Zailong Wang, Novartis
Shephard Mpofu, Novartis
Arthur Kavanaugh, University of Washington
Iain B. McInnes, University of California, San Diego
Philip J. Mease, University of Rochester Medical Center
Hector Chinoy, University of Manchester
J Alan

Disciplines

Physical Therapy and
Medicine and Health Sciences

Publication Date

January 1, 2017

Citation Information

Zailong Wang, Shephard Mpofu, Arthur Kavanaugh, Iain B. McInnes, et al.. "the Randomized Placebo-controlled FUTURE 2 Study Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic" (2017)
Available at: http://works.bepress.com/philip-mease/68/